Standout Papers

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a rand... 2023 2026 2024104
  1. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial (2023)
    Enriqueta Felip, Nasser K. Altorki et al. Annals of Oncology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 56 standout
Sub-graph 1 of 23

Citing Papers

Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
2024 Standout
Non-small-cell lung cancer
2024 Standout
3 intermediate papers

Works of Elizabeth Bennett being referenced

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
2023 Standout
2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
2021
and 2 more

Author Peers

Author Last Decade Papers Cites
Elizabeth Bennett 594 426 610 52 1.4k
Zahra Ghodsi 213 55 355 86 1.2k
Erin Parker 261 106 70 40 1.1k
Natalie Yanchar 317 118 322 95 1.6k
Li Yh 244 77 81 66 993
Kimberly Alexander 145 30 200 77 1.1k
Richard S. Riggins 206 127 86 56 1.3k
Rashid Jooma 207 116 83 69 1.3k
James P. Byrne 153 40 225 92 1.6k
Lu Pai 338 198 195 40 1.1k
Amina Khambalia 687 125 64 42 1.5k

All Works

Loading papers...

Rankless by CCL
2026